Bharat Biotech Collaborates With US-Based Alopexx to Develop Antimicrobial Vaccine
By Rhythma Kaul
As part of the collaboration, the companies will co-develop and commercialise the vaccine— AV0328— in India and other licensed territories, said Bharat Biotech in a formal statement.
Hyderabad-based Bharat Biotech on Wednesday announced its collaboration with US-based Alopexx Inc for development and commercialisation of the latter’s broad-spectrum anti-microbial vaccine in India and other low-income countries, which experts feel could be a game-changer in tackling the growing anti-microbial resistance (AMR) threat.
Photo courtesy of CDC.
Source: Hindustan Times (link opens in a new window)
- Categories
- Health Care
